

# Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.

share Share  
more\_vert

---

[article](#)

[Abstract](#)

---

## Details

- First Author

[Weili Zhao](#)

- Meeting

[2024 ASCO Annual Meeting](#)

- Session Type

[Oral Abstract Session](#)

- Session Title

[Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia](#)

- Track

[Hematologic Malignancies](#)

- Sub Track

[Non-Hodgkin Lymphoma](#)

- Clinical Trial Registration Number

NCT04231448

- Citation

J Clin Oncol 42, 2024 (suppl 17; abstr LBA7003)

- Abstract #

LBA7003

## Authors

person

**Weili Zhao**

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

info\_outline

Weili Zhao, Jun Zhu, Yuqin Song, Peng-Peng Xu, Jianzhen Shen, Qingqing Cai, Hui Zhou, Liling Zhang, Ying Xiang, Xiuhua Sun, Wei Yang, Zhihua Yao, Hongmei Jing, Shujuan Wen, Jie Jin, Hongwei Xue, Hong Cen, Kaiyang Ding, Zhengming Jin, Xiaojing Xing

#### **Organizations**

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China, Fujian Medical University Union Hospital, Fuzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Lymphoma & Hematology, Hunan Cancer Hospital, Changsha, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Chongqing University Cancer Hospital, Chongqing, China, The Second Hospital of Dalian Medical University, Dalian, China, Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China, Lymphatic Comprehensive Internal Medicine Ward, Henan Cancer Hospital, Zhengzhou, China, Peking University Third Hospital, Beijing, China, Xinjiang Medical University Affiliated Tumor Hospital, Wulumuqi, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China, The Affiliated Hospital of Qingdao University, Qingdao, China, Department of Medical Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China, The First Affiliated Hospital of USTC, Hefei, China, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China, Liaoning Cancer Hospital and Institute, Shenyang, China

#### [Abstract Disclosures](#)

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact [licensing@asco.org](mailto:licensing@asco.org)  
Recommended For You

To view items recommended for you, please sign in to your ASCO.org account. [Sign In chevron\\_right](#)